You are here

Bydureon

FDA offers former biotech unicorn Intarcia a chance for a panel review

FDA offers former biotech unicorn Intarcia a chance for a panel review

BioPharma Dive

Flag link:

ADA 2021: AstraZeneca touts Bydureon trial win in children and adolescents with type 2 diabetes

ADA 2021: AstraZeneca touts Bydureon trial win in children and adolescents with type 2 diabetes

Fierce Pharma

type 2 diabetes

clinical trials

Flag link:

How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes

How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes

Fierce Biotech

Flag link:

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Flag link:

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Fierce Biotech

Parkinson's Disease

Flag link:

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Flag link:

AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval

AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval

Drug Delivery Business News

Flag link:

FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo

FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo

Drug Delivery Business News

drug-device combos

Flag link:

AstraZeneca's Bydureon fails to show cardio-protection

AstraZeneca's Bydureon fails to show cardio-protection

BioPharma Dive

Flag link:

AZ's Bydureon cleared a heart safety test, but didn't cut risks. Can it still vie with Novo?

AZ's Bydureon cleared a heart safety test, but didn't cut risks. Can it still vie with Novo?

Fierce Pharma

Flag link:

Next stop in AstraZeneca fire sale: China

Next stop in AstraZeneca fire sale: China

BioPharma Dive

Flag link:

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

Yahoo

clinical trials

type 2 diabetes

Flag link:

Novo's weekly diabetes drug clears another Phase III hurdle

Novo's weekly diabetes drug clears another Phase III hurdle

Fierce Biotech

Flag link:

Bydureon, Invokana, Xarelto brand teams shelled out most to doctors in 2014

Bydureon, Invokana, Xarelto brand teams shelled out most to doctors in 2014

Fierce Pharma Marketing

physician payments

Flag link:

After Bristol Myers' Bydureon Success, The Next Step Is Sustained Release Insulin

After Bristol Myers' Bydureon Success, The Next Step Is Sustained Release Insulin

Seeking Alpha

Bristol-Myers Squibb

Flag link:

AstraZeneca announces FDA approval of Bydureon Pen

AstraZeneca announces FDA approval of Bydureon Pen

The Fly on the Wall

Flag link:

FDA eases worries regarding certain diabetes medications

FDA eases worries regarding certain diabetes medications

Yahoo/Fly on the Wall

Bristol-Myers Squibb

Flag link:

Who loses most in Lilly vs. Novo diabetes study? AstraZeneca

Who loses most in Lilly vs. Novo diabetes study? AstraZeneca

Fierce Pharma

Flag link:

Clock Is Ticking For AstraZeneca

Clock Is Ticking For AstraZeneca

Forbes

Flag link:

AstraZeneca, Bristol Recall Bydureon Diabetes Drug For Under-Filled Vials

AstraZeneca, Bristol Recall Bydureon Diabetes Drug For Under-Filled Vials

WSJ Online

Bristol-Myers Squibb

Flag link:

Pages